STADA Arzneimittel

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications. The Branded Products segment offers APO-Go a Parkinson’s medicine; Aqualor for rhinitis/sore throat; Grippostad a cold medicine; Snup for rhinitis; and Vitaprost for prostate disease indications, as well as Ladival a sun protection product. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy cooperatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany.
Type
Public
HQ
Bad Vilbel, DE
Founded
1895
Employees
10,809 (est)
STADA Arzneimittel was founded in 1895 and is headquartered in Bad Vilbel, DE

STADA Arzneimittel Locations

Bad Vilbel, DE

STADA Arzneimittel Metrics

STADA Arzneimittel Summary

Market capitalization

€2.78 B

Closing share price

€46
STADA Arzneimittel's latest market capitalization is €2.78 B.

STADA Arzneimittel Market Value History

STADA Arzneimittel Online Presence

STADA Arzneimittel News

STADA Arzneimittel Company Life